Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1961 1
1962 2
1964 3
1965 1
1970 1
1971 1
1973 1
1974 1
1975 1
1976 2
1980 1
1982 1
1985 1
1986 4
1987 3
1988 2
1990 6
1991 7
1992 2
1993 4
1994 2
1995 3
1996 4
1997 3
1998 9
1999 5
2000 6
2001 7
2002 9
2003 14
2004 20
2005 20
2006 22
2007 14
2008 18
2009 14
2010 17
2011 20
2012 12
2013 25
2014 32
2015 35
2016 43
2017 40
2018 52
2019 67
2020 63
2021 86
2022 81
2023 65
2024 25

Text availability

Article attribute

Article type

Publication date

Search Results

770 results

Results by year

Filters applied: . Clear all
Page 1
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.
Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi T, Lin Y, Timmerman JM, Stiff PJ, Friedberg JW, Flinn IW, Goy A, Hill BT, Smith MR, Deol A, Farooq U, McSweeney P, Munoz J, Avivi I, Castro JE, Westin JR, Chavez JC, Ghobadi A, Komanduri KV, Levy R, Jacobsen ED, Witzig TE, Reagan P, Bot A, Rossi J, Navale L, Jiang Y, Aycock J, Elias M, Chang D, Wiezorek J, Go WY. Neelapu SS, et al. Among authors: chavez jc. N Engl J Med. 2017 Dec 28;377(26):2531-2544. doi: 10.1056/NEJMoa1707447. Epub 2017 Dec 10. N Engl J Med. 2017. PMID: 29226797 Free PMC article. Clinical Trial.
Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma.
Neelapu SS, Jacobson CA, Ghobadi A, Miklos DB, Lekakis LJ, Oluwole OO, Lin Y, Braunschweig I, Hill BT, Timmerman JM, Deol A, Reagan PM, Stiff P, Flinn IW, Farooq U, Goy AH, McSweeney PA, Munoz J, Siddiqi T, Chavez JC, Herrera AF, Bartlett NL, Bot AA, Shen RR, Dong J, Singh K, Miao H, Kim JJ, Zheng Y, Locke FL. Neelapu SS, et al. Among authors: chavez jc. Blood. 2023 May 11;141(19):2307-2315. doi: 10.1182/blood.2022018893. Blood. 2023. PMID: 36821768 Free PMC article.
Consensus on hemophilia in Mexico.
López-Arroyo JL, Pérez-Zúñiga JM, Merino-Pasaye LE, Saavedra-González A, Alcivar-Cedeño LM, Álvarez-Vera JL, Anaya-Cuellar I, Arana-Luna LL, Ávila-Castro D, Bates-Martín RA, Cesarman-Maus G, Chávez-Aguilar LA, Peña-Celaya JA, Espitia-Ríos ME, Estrada-Domínguez P, Fermín-Caminero D, Flores-Patricio W, Chávez JG, García-Lee MT, González-Pérez MDC, González-Rubio MDC, González-Villareal MG, Ramírez-Moreno F, Hernández-Colin AK, Hernández-Ruiz E, Herrera-Olivares W, Leyto-Cruz F, Loera-Fragoso S, Martínez-Ríos A, Miranda-Madrazo MR, Morales-Hernández A, Nava-Villegas L, Orellana-Garibay JJ, Palma-Moreno OG, Paredes-Lozano EP, Peña-Alcántara P, Pérez-Lozano U, Pichardo-Cepín YM, Reynoso-Pérez AC, Rodríguez-Serna M, Rojas-Castillejos F, Romero-Rodelo H, Ruíz-Contreras JI, Segura-García A, Silva-Vera K, Soto-Cisneros PM, Tapia-Enríquez AL, Tavera-Rodríguez MG, Teomitzi-Sánchez Ó, Tepepa-Flores F, Valencia-Rivas MD, Valle-Cárdenas T, Varela-Constantino A, Javier-Morales A, Martínez-Ramírez MA, Tena-Cano S, Terrazas-Marín R, Vilchis-González SP, Villela-Peña A, Mena-Zepeda V, Ibarra MA. López-Arroyo JL, et al. Among authors: chavez jg. Gac Med Mex. 2021;157(Suppl 1):S1-S35. doi: 10.24875/GMM.M21000463. Gac Med Mex. 2021. PMID: 33819260 Free article. English.
Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial.
Jacobson CA, Chavez JC, Sehgal AR, William BM, Munoz J, Salles G, Munshi PN, Casulo C, Maloney DG, de Vos S, Reshef R, Leslie LA, Yakoub-Agha I, Oluwole OO, Fung HCH, Rosenblatt J, Rossi JM, Goyal L, Plaks V, Yang Y, Vezan R, Avanzi MP, Neelapu SS. Jacobson CA, et al. Among authors: chavez jc. Lancet Oncol. 2022 Jan;23(1):91-103. doi: 10.1016/S1470-2045(21)00591-X. Epub 2021 Dec 8. Lancet Oncol. 2022. PMID: 34895487 Clinical Trial.
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial.
Fowler NH, Dickinson M, Dreyling M, Martinez-Lopez J, Kolstad A, Butler J, Ghosh M, Popplewell L, Chavez JC, Bachy E, Kato K, Harigae H, Kersten MJ, Andreadis C, Riedell PA, Ho PJ, Pérez-Simón JA, Chen AI, Nastoupil LJ, von Tresckow B, Ferreri AJM, Teshima T, Patten PEM, McGuirk JP, Petzer AL, Offner F, Viardot A, Zinzani PL, Malladi R, Zia A, Awasthi R, Masood A, Anak O, Schuster SJ, Thieblemont C. Fowler NH, et al. Among authors: chavez jc. Nat Med. 2022 Feb;28(2):325-332. doi: 10.1038/s41591-021-01622-0. Epub 2021 Dec 17. Nat Med. 2022. PMID: 34921238 Free article. Clinical Trial.
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.
Locke FL, Ghobadi A, Jacobson CA, Miklos DB, Lekakis LJ, Oluwole OO, Lin Y, Braunschweig I, Hill BT, Timmerman JM, Deol A, Reagan PM, Stiff P, Flinn IW, Farooq U, Goy A, McSweeney PA, Munoz J, Siddiqi T, Chavez JC, Herrera AF, Bartlett NL, Wiezorek JS, Navale L, Xue A, Jiang Y, Bot A, Rossi JM, Kim JJ, Go WY, Neelapu SS. Locke FL, et al. Among authors: chavez jc. Lancet Oncol. 2019 Jan;20(1):31-42. doi: 10.1016/S1470-2045(18)30864-7. Epub 2018 Dec 2. Lancet Oncol. 2019. PMID: 30518502 Free PMC article. Clinical Trial.
Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial.
Neelapu SS, Dickinson M, Munoz J, Ulrickson ML, Thieblemont C, Oluwole OO, Herrera AF, Ujjani CS, Lin Y, Riedell PA, Kekre N, de Vos S, Lui C, Milletti F, Dong J, Xu H, Chavez JC. Neelapu SS, et al. Among authors: chavez jc. Nat Med. 2022 Apr;28(4):735-742. doi: 10.1038/s41591-022-01731-4. Epub 2022 Mar 21. Nat Med. 2022. PMID: 35314842 Free PMC article. Clinical Trial.
Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5).
Neelapu SS, Chavez JC, Sehgal AR, Epperla N, Ulrickson M, Bachy E, Munshi PN, Casulo C, Maloney DG, de Vos S, Reshef R, Leslie LA, Oluwole OO, Yakoub-Agha I, Khanal R, Rosenblatt J, Korn R, Peng W, Lui C, Wulff J, Shen R, Poddar S, Jung AS, Miao H, Beygi S, Jacobson CA. Neelapu SS, et al. Among authors: chavez jc. Blood. 2024 Feb 8;143(6):496-506. doi: 10.1182/blood.2023021243. Blood. 2024. PMID: 37879047 Free PMC article.
In vivo partial cellular reprogramming enhances liver plasticity and regeneration.
Hishida T, Yamamoto M, Hishida-Nozaki Y, Shao C, Huang L, Wang C, Shojima K, Xue Y, Hang Y, Shokhirev M, Memczak S, Sahu SK, Hatanaka F, Ros RR, Maxwell MB, Chavez J, Shao Y, Liao HK, Martinez-Redondo P, Guillen-Guillen I, Hernandez-Benitez R, Esteban CR, Qu J, Holmes MC, Yi F, Hickey RD, Garcia PG, Delicado EN, Castells A, Campistol JM, Yu Y, Hargreaves DC, Asai A, Reddy P, Liu GH, Izpisua Belmonte JC. Hishida T, et al. Among authors: chavez j. Cell Rep. 2022 Apr 26;39(4):110730. doi: 10.1016/j.celrep.2022.110730. Cell Rep. 2022. PMID: 35476977 Free PMC article.
770 results